Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children

• Published in: Blood 2002-08, Vol.100 (3), p.786-790
• Main Authors: Kojima, Seiji, Ohara, Akira, Tsuchida, Masahiro, Kudoh, Toru, Hanada, Ryoji, Okimoto, Yuri, Kaneko, Takashi, Takano, Toshikuni, Ikuta, Koichiro, Tsukimoto, Ichiro
• Format: Article
• Language: English
• Subjects: Acute Disease; Adolescent; Adult; Anemia, Aplastic - drug therapy; Anemia, Aplastic - genetics; Anemia, Aplastic - pathology; Anemias. Hemoglobinopathies; Biological and medical sciences; Child; Child, Preschool; Chromosomes, Human, Pair 7; Diseases of red blood cells; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - adverse effects; Hematologic and hematopoietic diseases; Humans; Immunosuppressive Agents - adverse effects; Incidence; Infant; Karyotyping; Leukemia, Myeloid - chemically induced; Leukemia, Myeloid - etiology; Leukemia, Myeloid - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Monosomy; Myelodysplastic Syndromes - chemically induced; Myelodysplastic Syndromes - etiology; Myelodysplastic Syndromes - genetics; Prospective Studies; Risk Factors; Survival Rate
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V100.3.786

Long-term survivors of acquired aplastic anemia (AA) have an increased risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST). It is uncertain whether the increased survival time simply discloses the natural history of AA as a premalignant disease or whether secondary disease is related to the therapy itself. Between November 1992 and September 1997, 113 AA children with normal cytogenetics at diagnosis were treated with IST using antithymocyte globulin, cyclosporin, and danazol with or without granulocyte colony-stimulating factor (G-CSF). We assessed risk factors for developing MDS/AML by Cox proportional hazards models. Twelve of 113 patients developed MDS between 9 and 81 months following the time of diagnosis, giving a cumulative incidence of 13.7 ± 3.9%. The following cytogenetic abnormalities were observed at the time of diagnosis of MDS: monosomy 7 (6 patients), monosomy7/trisomy21 (1 patient), trisomy 11 (1 patient), del (11) (9?:14) (1 patient), add (9q) (1 patient), add 7 (q 32) (1 patient), and trisomy 9 (1 patient). The number of days of G-CSF therapy and nonresponse to therapy at 6 months were statistically significant risk factors by multivariate analysis. The present study suggests a close relationship between long-term use of G-CSF and secondary MDS in nonresponders to IST.